Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland

被引:0
作者
Micha, Maeder T. [1 ]
Tabea, Konig [1 ]
Sanja, Bogdanovic [1 ]
Irene, Schneider [1 ]
Werner, Eugster [2 ,3 ]
Peter, Ammann [1 ]
Marius, Konig [5 ]
Jurg, Beer H. [4 ]
Hans, Rickli [1 ]
机构
[1] Kantonsspital St Gallen, Cardiol Dept, Rorschacherstr 95, CH-9007 St Gallen, Switzerland
[2] Herzteam Wil, Wil, Switzerland
[3] Aerztenetz Xundart, Wil, Switzerland
[4] Kantonsspital St Gallen, Internal Med Dept, St Gallen, Switzerland
[5] Univ Hosp Zurich, Kantonsspital Baden & Mol Cardiol, Internal Med Dept, Zurich, Switzerland
关键词
oral anticoagulation; atrial fibrillation; vitamin K antagonist; non-vitamin K antagonist oral anticoagulation; time to therapeutic range; INR; STROKE PREVENTION; COST-EFFECTIVENESS; WARFARIN; DABIGATRAN; METAANALYSIS; RIVAROXABAN; MANAGEMENT; APIXABAN; THERAPY; RANGE;
D O I
10.4414/smw.2017.w14503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AIM OF THE STUDY: To better appreciate the role of the non-vitamin K oral anticoagulants (NOACs) for patients with non-valvular atrial fibrillation in Switzerland we aimed to assess the quality of vitamin K antagonist (VKA) anticoagulation in daily practice. METHODS: In a cross-sectional study, clinically stable patients on VKA treatment for non-valvular atrial fibrillation for at least 6 months, documentation of international normalised ratio (INR) values for at least 3 months and with at least two INR values were included. The percentage of INR values within the therapeutic range of 2.0 to 3.0 and the time in therapeutic range (TTR; Rosendaal method) and predictors for these measures of VKA anticoagulation quality were assessed. RESULTS: We studied 332 patients (62% male, mean age 74 +/- 9 years) with median (interquartile range) CHA(2)DS(2)Vasc and HAS-BLED scores of 4 (3-5) and 3 (2-4) points. The median number of INR values per patient was 8 (5-14), and the average interval between INR measurements was 20 (13-27) days. The percentage of INR values between 2.0 and 3.0 was 67% (50-83%). The median TTR was 69% (51-89%), and TTR >= 65% was found in 202 (61%) patients. Independent predictors of >= 80% INR values between 2.0 and 3.0 included a longer interval between INR measurements and the non-use of spironolactone. The non-use of amiodarone and spironolactone and a longer interval between INR measurements were the only independent predictors of a TTR >= 65%. CONCLUSIONS: The quality of VKA anticoagulation in Switzerland is highly variable. Importantly, only 60% of patients achieve a TTR >= 65%, which is currently considered to be the minimal acceptable TTR required for VKA therapy. There are few clinical predictors of a good VKA anticoagulation quality. These data may represent a novel basis for decision making regarding the choice of anticoagulation for atrial fibrillation in Switzerland.
引用
收藏
页数:6
相关论文
共 24 条
[1]   Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Ageno, Walter ;
Gallus, Alexander S. ;
Wittkowsky, Ann ;
Crowther, Mark ;
Hylek, Elaine M. ;
Palareti, Gualtiero .
CHEST, 2012, 141 (02) :E44S-E88S
[2]   Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM) [J].
Ansell, Jack ;
Hollowell, Jennifer ;
Pengo, Vittorio ;
Martinez-Brotons, Fernando ;
Caro, Jaime ;
Drouet, Ludovic .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2007, 23 (02) :83-91
[3]   Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT2R2 Score [J].
Apostolakis, Stavros ;
Sullivan, Renee M. ;
Olshansky, Brian ;
Lip, Gregory Y. H. .
CHEST, 2013, 144 (05) :1555-1563
[4]   Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States [J].
Baker, William L. ;
Cios, Deborah A. ;
Sander, Stephen D. ;
Coleman, Craig I. .
JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (03) :244-252
[5]   Vitamin K antagonists are hard to beat by the price - are they? Some answers, new questions and the GPs' dilemma [J].
Beer, Juerg H. .
SWISS MEDICAL WEEKLY, 2013, 143
[6]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[7]   National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation [J].
Dlott, Jeffrey S. ;
George, Roberta A. ;
Huang, Xiaohua ;
Odeh, Mouneer ;
Kaufman, Harvey W. ;
Ansell, Jack ;
Hylek, Elaine M. .
CIRCULATION, 2014, 129 (13) :1407-1414
[8]   Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation [J].
Freeman, James V. ;
Zhu, Ruo P. ;
Owens, Douglas K. ;
Garber, Alan M. ;
Hutton, David W. ;
Go, Alan S. ;
Wang, Paul J. ;
Turakhia, Mintu P. .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) :1-U129
[9]   Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients [J].
Gallagher, Arlene M. ;
Setakis, Efrosini ;
Plumb, Jonathan M. ;
Clemens, Andreas ;
van Staa, Tjeerd-Pieter .
THROMBOSIS AND HAEMOSTASIS, 2011, 106 (05) :968-977
[10]   Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].
Giugliano, Robert P. ;
Ruff, Christian T. ;
Braunwald, Eugene ;
Murphy, Sabina A. ;
Wiviott, Stephen D. ;
Halperin, Jonathan L. ;
Waldo, Albert L. ;
Ezekowitz, Michael D. ;
Weitz, Jeffrey I. ;
Spinar, Jindrich ;
Ruzyllo, Witold ;
Ruda, Mikhail ;
Koretsune, Yukihiro ;
Betcher, Joshua ;
Shi, Minggao ;
Grip, Laura T. ;
Patel, Shirali P. ;
Patel, Indravadan ;
Hanyok, James J. ;
Mercuri, Michele ;
Vogelmann, O. ;
Gonzalez, C. ;
Ahuad Guerrero, R. ;
Rodriguez, M. ;
Albisu, J. ;
Rosales, E. ;
Allall, O. ;
Reguero, M. ;
Alvarez, C. ;
Garcia, M. ;
Ameriso, S. ;
Ameriso, P. ;
Amuchastegui, M. ;
Caceres, M. ;
Beloscar, J. ;
Petrucci, J. ;
Berli, M. ;
Budassi, N. ;
Valle, M. ;
Bustamante Labarta, G. ;
Saravia, M. ;
Caccavo, A. ;
Fracaro, V. ;
Cartasegna, L. ;
Novas, V. ;
Caruso, O. ;
Saa Zarandon, R. ;
Colombo, H. ;
Morandini, M. ;
Cuello, J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104